Department of Clinical Cardiology, National Institute Cardiology Ignacio Chávez, Mexico City, Mexico.
Cardiovascular Post-Surgical Unit, National Institute of Child Health, Lima, Peru.
Arch Cardiol Mex. 2021 Dec 20;91(Suplemento COVID):079-085. doi: 10.24875/ACM.20000234.
In severe coronavirus disease (COVID)-19 patients, an extraordinary systemic inflammatory response is seen. It could impact in multiple organ disorders, specially a severe myocardial injury, an acute myocarditis results in focal or global myocardial inflammation and necrosis. Those events can be present in healthy subjects or cardiovascular (CV) patients. It is clinically associated with ventricular dysfunction exacerbation or worsening and tachyarrhythmias. It is also related to a poor outcome for CV patients with ischemic heart disease, hypertensión, and heart failure. COVID-19 patients require multiple and complex treatment that alleviates symptoms, the vast variety of agents interacts with diseases and CV drugs. Our purpose is to correlate in guidance synopsis: Adverse effects, pharmacological interactions, and CV drugs in COVID-19 treatment.
在严重的冠状病毒病（COVID-19）患者中，会出现异常的全身炎症反应。它可能会影响多个器官的功能紊乱，特别是严重的心肌损伤，急性心肌炎会导致局灶性或全球性心肌炎症和坏死。这些事件可能发生在健康受试者或心血管（CV）患者中。它与心室功能障碍加重或恶化以及心动过速性心律失常有关。它也与患有缺血性心脏病、高血压和心力衰竭的 CV 患者的不良预后相关。COVID-19 患者需要接受多种复杂的治疗以缓解症状，大量的药物与疾病和 CV 药物相互作用。我们的目的是在指南摘要中关联：COVID-19 治疗中的不良反应、药物相互作用和 CV 药物。
